Zobrazeno 1 - 5
of 5
pro vyhledávání: '"PG Mortimer"'
Publikováno v:
Palliative Medicine. 11:475-482
The efficacy, tolerability and 24-h duration of action of MXL® capsules, a novel once-daily morphine preparation, were compared with twice-daily morphine tablets (MST Continus® tablets) in patients with severe cancer pain. Eighty-five patients were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1951ecbb84f19fc707d13e04dd876f46
https://doi.org/10.1177/026921639701100608
https://doi.org/10.1177/026921639701100608
Autor:
Choudhury AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Higano CS; Department of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington., de Bono JS; Drug Development Unit, The Institute of Cancer Research and Royal Marsden, London, United Kingdom., Cook N; The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom., Rathkopf DE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, New York., Wisinski KB; Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Martin-Liberal J; Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain., Linch M; University College London (UCL) Cancer Institute and UCL Hospital, London, United Kingdom., Heath EI; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan., Baird RD; Cancer Research UK Cambridge Center, Cambridge, United Kingdom., García-Carbacho J; Department of Medical Oncology (Hospital Clinic Barcelona)/Translational Genomics and Targeted Therapies in Solid Tumors (IDIBAPS), Barcelona, Spain., Quintela-Fandino M; Hospital Universitario, Quiron Madrid, Madrid, Spain., Barry ST; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., de Bruin EC; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Colebrook S; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hawkins G; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Klinowska T; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Maroj B; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Moorthy G; Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, Massachusetts., Mortimer PG; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Moschetta M; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Nikolaou M; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Sainsbury L; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Hansen AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jun 01; Vol. 28 (11), pp. 2257-2269.
Publikováno v:
Palliative medicine [Palliat Med] 1997 Nov; Vol. 11 (6), pp. 475-82.
Autor:
Mortimer PG; Department of Infection, University of Birmingham, UK., Piddock LJ
Publikováno v:
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 1993 Aug; Vol. 32 (2), pp. 195-213.
Autor:
Mortimer PG; Department of Medical Microbiology, University of Birmingham, UK., Piddock LJ
Publikováno v:
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 1991 Nov; Vol. 28 (5), pp. 639-53.